GlassScriptPhysician profile
Laxmi Deepika Koya
NPI 1205883832
$1,057.89
in general payments reported to CMS, 2019-2025
19 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $137 · 2021: $29.77 · 2022: $57.13 · 2023: $92.35 · 2024: $89.32 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $197.13 | 2019-2025 | |
| Madrigal Pharmaceuticals | $195.07 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.35 | 2019-2023 | Xifaxan |
| Pfizer INC. | $86.50 | 2019-2022 | |
| Qol Medical, LLC | $71.87 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.72 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $39.39 | 2024-2025 | Zenpep |
| Celgene Corporation | $31.89 | 2024 | Zeposia |
| Allergan, INC. | $25.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.08 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $21.75 | 2020 | |
| Concordia Pharmaceuticals INC. | $19.54 | 2019 | |
| Boston Scientific Corporation | $16.93 | 2021 | |
| Redhill Biopharma INC. | $16.92 | 2020 | |
| Nestle Healthcare Nutrition INC. | $16.78 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $15.96 | 2019 | |
| Janssen Biotech, INC. | $14.59 | 2022 | |
| Braintree Laboratories, INC. | $13.65 | 2019 | |
| Intercept Pharmaceuticals, INC. | $8.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laxmi Koya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.